<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>For post surgical indications:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="103704">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of dabigatran</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="103704">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="103704">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.</COMMENT>
</INTERACTION>
</INTERACTIONS>
